| Primary |
| Immunosuppression |
19.8% |
| Lepromatous Leprosy |
17.3% |
| Diffuse Large B-cell Lymphoma |
12.3% |
| Takayasu's Arteritis |
7.4% |
| Haemangioma |
6.2% |
| Renal Transplant |
4.9% |
| Immunosuppressant Drug Therapy |
3.7% |
| Nephrotic Syndrome |
3.7% |
| Prostate Cancer |
3.7% |
| Colitis Ulcerative |
2.5% |
| Erythema Multiforme |
2.5% |
| Hyperuricaemia |
2.5% |
| Myasthenia Gravis |
2.5% |
| Non-hodgkin's Lymphoma |
2.5% |
| Prophylaxis |
2.5% |
| Arthritis |
1.2% |
| Bronchopulmonary Aspergillosis |
1.2% |
| Connective Tissue Disorder |
1.2% |
| Interstitial Lung Disease |
1.2% |
| Organising Pneumonia |
1.2% |
|
| Toxicity To Various Agents |
21.2% |
| Type 2 Lepra Reaction |
21.2% |
| Interstitial Lung Disease |
6.1% |
| Adrenal Insufficiency |
3.0% |
| Breast Cancer |
3.0% |
| Cardiac Failure |
3.0% |
| Cystoid Macular Oedema |
3.0% |
| Hepatic Failure |
3.0% |
| Large Intestine Perforation |
3.0% |
| Macular Fibrosis |
3.0% |
| Meningitis Cryptococcal |
3.0% |
| Neoplasm Skin |
3.0% |
| Oesophageal Ulcer |
3.0% |
| Pancytopenia |
3.0% |
| Pemphigus |
3.0% |
| Pneumocystis Jirovecii Pneumonia |
3.0% |
| Progressive Multifocal Leukoencephalopathy |
3.0% |
| Proteinuria |
3.0% |
| Pseudomonas Infection |
3.0% |
| Renal Failure Acute |
3.0% |
|
| Secondary |
| Product Used For Unknown Indication |
18.7% |
| Rheumatoid Arthritis |
13.1% |
| Burkitt's Lymphoma |
9.3% |
| Hepatitis C |
5.6% |
| Prophylaxis Against Renal Transplant Rejection |
4.7% |
| Renal Transplant |
4.7% |
| Immunosuppressant Drug Therapy |
3.7% |
| Lichen Myxoedematosus |
3.7% |
| Prophylaxis |
3.7% |
| Systemic Lupus Erythematosus |
3.7% |
| Transplant Rejection |
3.7% |
| Chronic Lymphocytic Leukaemia |
2.8% |
| Hashimoto's Encephalopathy |
2.8% |
| Ill-defined Disorder |
2.8% |
| Immunosuppression |
2.8% |
| Lupus Nephritis |
2.8% |
| Nephrotic Syndrome |
2.8% |
| Pemphigus |
2.8% |
| Peripheral T-cell Lymphoma Unspecified |
2.8% |
| Pneumonia |
2.8% |
|
| Respiratory Failure |
12.5% |
| Pyelonephritis Acute |
8.3% |
| Sepsis |
8.3% |
| Blindness Unilateral |
4.2% |
| Chorioretinopathy |
4.2% |
| Cytomegalovirus Infection |
4.2% |
| Haematemesis |
4.2% |
| Hypertriglyceridaemia |
4.2% |
| Leukopenia |
4.2% |
| Lung Infection |
4.2% |
| Necrotising Fasciitis |
4.2% |
| Nephrolithiasis |
4.2% |
| Neutrophil Count Decreased |
4.2% |
| Oesophageal Varices Haemorrhage |
4.2% |
| Off Label Use |
4.2% |
| Parotitis |
4.2% |
| Pericardial Effusion |
4.2% |
| Pneumocystis Jirovecii Pneumonia |
4.2% |
| Pneumonia Aspiration |
4.2% |
| Pneumonia Necrotising |
4.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
34.0% |
| Chronic Lymphocytic Leukaemia |
9.0% |
| Depression |
6.9% |
| Plasma Cell Myeloma |
4.9% |
| Hypertension |
4.2% |
| Immunosuppression |
4.2% |
| Osteoporosis |
4.2% |
| Rheumatoid Arthritis |
4.2% |
| Type 1 Diabetes Mellitus |
4.2% |
| Neutropenic Sepsis |
3.5% |
| Prophylaxis |
3.5% |
| Neuralgia |
2.8% |
| Osteoporosis Prophylaxis |
2.8% |
| Scleritis |
2.8% |
| Cardiac Failure |
2.1% |
| B-cell Small Lymphocytic Lymphoma |
1.4% |
| Aplastic Anaemia |
1.4% |
| Cellulitis |
1.4% |
| Diffuse Large B-cell Lymphoma |
1.4% |
| Epilepsy |
1.4% |
|
| Paraesthesia |
14.5% |
| Treatment Failure |
9.7% |
| Vomiting |
9.7% |
| Weight Decreased |
6.5% |
| Glossitis |
4.8% |
| Renal Impairment |
4.8% |
| Sepsis |
4.8% |
| Stomatitis |
4.8% |
| Therapeutic Response Unexpected |
4.8% |
| Atrial Fibrillation |
3.2% |
| Erythema |
3.2% |
| Femur Fracture |
3.2% |
| Hallucination |
3.2% |
| Hypersensitivity |
3.2% |
| Lip Swelling |
3.2% |
| Mood Swings |
3.2% |
| Myasthenia Gravis |
3.2% |
| Neutropenic Sepsis |
3.2% |
| Pericardial Effusion |
3.2% |
| Rhinitis Allergic |
3.2% |
|
